Evidence map›Paper›PMID 24272818›Full record

ArticleOncotarget2013

Mouse models and anti-HER2 therapies.

Ariella B Hanker, Rebecca S Cook, Carlos L Arteaga

Abstract readNews
In one paragraph

Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ariella B HankerDepartments of Medicine and Cancer Biology, Breast Cancer Research Program, Vanderbilt- Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
Rebecca S Cook
Carlos L Arteaga

Funding

TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCERR01CA080195 · NCI · VANDERBILT UNIVERSITY · PI ARTEAGA, CARLOS L · 1999 to 2014
$3.9M
NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA080195
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDisease Models, AnimalErb-b2 Receptor Tyrosine KinasesFemaleMammary Neoplasms, ExperimentalMiceMolecular Targeted TherapyPhenotypeErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID24272818
PMCPMC3875754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.